NEW YORK, Sept. 21, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter Magazine has published exclusive interviews with the CEOs of three dynamic companies -- Specialty Scanners, RoxRo Pharma and DC Brands International (Pink Sheets:DCBI) -- taking approaches to human biological needs that range from conventional drug development to diagnostic technologies to next-generation energy beverages.
All interviews are available at www.wallstreetreporter.com in streaming audio format -- free of charge.
Specialty Scanners plc has developed a proprietary magnetic resonance imaging (MRI) scanning system that not only scans target areas but guides probes to them for minimally invasive biopsy or therapeutic purposes.
"The scanner can support interactive and real-time image guidance of a biopsy needle to a target lesion in order to take a biopsy," explains Dr. Ali Akgun, the company's CEO. Also, the scanner can give support beyond the biopsy if it is appropriate for that particular patient; for example, a cryoprobe could be targeted to the lesion."
Topics of interest to potential investors include:
-- Notes on the company's updated business plan, which now includes
the sale of equipment as well as the creation of diagnostic/care
centers.
-- How the technology is suited to its initial target market of
breast cancer, while the potential to diversify into other cancer
areas and broader medical applications remains substantial.
-- Ongoing efforts to expand an existing U.K.-based clinical network
through U.S. partners.
RoxRo Pharma Inc. helped pioneer the now-popular "virtual" drug development model by taking its lead program, an intranasal formulation of injection-only painkiller ketolorac, from Phase I all the way through Phase III.
"We have demonstrated our ability to execute effectively," says Dr. Roberto Rosenkranz, the privately held company's CEO. "We're on track to file an NDA in the first half of 2008."
Highlights include:
-- The history of the molecule as an injectable analgesic and why it
"never really panned out" for oral dosage.
-- The clinical advantages of moving the well-known molecule into a
form suitable for self-administration by outpatients.
-- Management's emphasis on lowering the company's risk profile while
retaining flexibility.
DC Brands International LLC (Pink Sheets:DCBI) has seen sales of its next-generation energy drink "taking off like crazy," says CEO Richard Pearce. "It's happening very quickly now."
Highlights include:
-- The company's taste-driven competitive strategy.
-- Early positive results from a promotional relationship with Nascar,
whose fans "are absolutely in love with this product."
-- Management's broad experience in the soda and
nutraceutical-enhanced beverage industries.
-- The successful retooling of the company's packaging supply chain to
eliminate problems that previously emerged on that front.
"We can beat them at the cash register," Mr. Pearce tells WSR. "We're ready to start franchising."
About Wall Street Reporter
Wall Street Reporter (Est. 1843) helps smart investors connect with exciting companies, through our website, magazines and conferences. The company's analysts produce in-depth, unbiased, unfiltered interviews that deliver a first-hand, straight-from-the-source perspective.
About Specialty Scanners plc
The business model of the Specialty Group is to research and develop novel magnetic resonance scanners for use in the clinical management of cancer, to sell scanners to clinical service providers and to establish dedicated clinical assessment and treatment centers using its proprietary scanners.
About RoxRo Pharma Inc.
RoxRo Pharma Inc. is a privately-owned specialty pharmaceutical company focused on the treatment of pain. Founded in 1999, RoxRoin-licenses promising drug candidates for rapid development in acute medical conditions.
About DC Brands International LLC
DC Brands International markets its Dickens Energy Cider through an ever-growing network of established distributors across the country as well as a line of apparel and other merchandise emblazoned with eye-catching logos.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated. The company has no obligation to update these forward-looking statements.